A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor Patients

Observational, Prospective, Multi-centric Study Exploring HER2 Mutations Incidence and Therapeutic Management in aNSCLC

NCT07356544 ·Status: RECRUITING

Stage III NSCLC RWE in Chinese Patients

NCT04023812 ·Status: COMPLETED

Single Center Registration Study on HER2 Expression and Clinical Pathological Characteristics in Prostate Cancer

NCT06146114 ·Status: RECRUITING

DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With HER2 IHC2+/3+ ESCC

NCT06055153 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT07003321 ·Status: RECRUITING ·Phase: PHASE2

A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC

NCT04580498 ·Status: UNKNOWN ·Phase: PHASE2

EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC

NCT02988141 ·Status: UNKNOWN

A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC

NCT05246514 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer

NCT03651219 ·Status: UNKNOWN ·Phase: PHASE3

An Exploratory Basket Study of Pyrotinib Maleate Tablets in HER2 Mutated or Amplified of Metastatic Solid Tumors

NCT05274191 ·Status: UNKNOWN ·Phase: PHASE2

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

NCT04619004 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors

NCT02500199 ·Status: UNKNOWN ·Phase: PHASE1

Detection of EGFR Mutations in the Blood of Patients With Non-small Cell Lung Cancer: a Feasibility Study

NCT00717002 ·Status: COMPLETED

A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete Resection

NCT05514314 ·Status: UNKNOWN ·Phase: PHASE2

Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation

NCT01204307 ·Status: COMPLETED ·Phase: PHASE2

Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)

NCT02979821 ·Status: COMPLETED ·Phase: PHASE2

Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC)

NCT00600587 ·Status: COMPLETED ·Phase: PHASE2

A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).

NCT05141786 ·Status: UNKNOWN ·Phase: PHASE2

Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT00536107 ·Status: TERMINATED ·Phase: PHASE4

Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY]

NCT04059887 ·Status: COMPLETED ·Phase: PHASE4

Afatinib in NSCLC With HER2 Mutation

NCT02597946 ·Status: COMPLETED ·Phase: PHASE2

A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT07232849 ·Status: RECRUITING ·Phase: PHASE2

A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation

NCT05745740 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2

Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients

NCT04560452 ·Status: COMPLETED

Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC

NCT02140333 ·Status: UNKNOWN ·Phase: PHASE3